v3.25.1
Segment Information - Schedule of Segment Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Revenues $ 5,392 $ 6,471
Research and development 36,442 38,065
Other segment expenses [1] 8,826 6,320
Net loss (39,876) (37,914)
TNG462 direct program expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development 5,461 5,086
TNG456 direct program expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development 1,324 0
TNG260 direct program expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development 1,730 2,236
TNG961 direct program expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development 2,221 0
TNG908 direct program expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development [2] 1,712 4,258
TNG348 direct program expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development [3] 0 3,300
Discovery direct program expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development 4,679 5,511
Personnel-related expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development 13,850 12,798
Facilities and Other Related Expenses - R&D [Member]    
Segment Reporting Information [Line Items]    
Research and development $ 5,465 $ 4,876
[1] Other segment expenses included in Segment net loss includes general and administrative expense, interest income, other income and provision for income taxes.
[2] In November 2024, we announced we stopped enrollment of the TNG908 Phase 1/2 clinical trial due to insufficient brain exposure for clinical activity in GBM patients and portfolio prioritization. Expenses beyond November 2024 related to previously enrolled patients and close-out clinical trial costs.
[3] In May 2024, we announced the discontinuation of TNG348, a USP1 inhibitor, due to toxicity observed in the dose escalation portion of our Phase 1/2 clinical trial. Expenses beyond May 2024 related to close-out clinical trial costs.